Jardiance (Empagliflozin) Regulatory Status: US, EU, Canada, and UK

How Empagliflozin Works: Mechanism of Action

Empagliflozin is a selective inhibitor of sodium-glucose cotransporter 2 (SGLT2), a protein expressed in the proximal tubule of the kidney that reabsorbs roughly 90% of filtered glucose. By blocking SGLT2, empagliflozin forces the kidney to excrete approximately 60 to 80 grams of glucose per day through urine, lowering blood glucose independently of insulin secretion [1].

This glycosuric effect is only part of the story. The drug also reduces plasma volume through osmotic diuresis and natriuresis, lowering both preload and afterload on the heart. A 2020 analysis published in Circulation estimated that empagliflozin reduces interstitial fluid volume without depleting intravascular volume to the same degree as loop diuretics [2]. That distinction matters for patients with heart failure, where excessive intravascular depletion can trigger hypotension and renal injury.

Empagliflozin also shifts myocardial fuel metabolism. Preclinical data and clinical biomarker studies suggest SGLT2 inhibitors increase circulating ketone bodies, particularly beta-hydroxybutyrate, providing the failing heart with a more efficient energy substrate than free fatty acids [3]. Researchers at the Mount Sinai Heart Failure Center have described this as a "metabolic rescue" effect, though the precise contribution of ketone metabolism to clinical outcomes remains under active investigation.

The weight loss observed with empagliflozin (typically 2 to 3 kg over 6 to 12 months) results from caloric loss through glucosuria, not appetite suppression. Blood pressure drops by an average of 4 to 5 mmHg systolic, which appears to reflect volume effects rather than direct vasodilation [1].

United States: FDA Approval Timeline

The FDA approved empagliflozin 10 mg and 25 mg tablets on August 1, 2014, under New Drug Application 204629, for improving glycemic control in adults with type 2 diabetes [4]. The approval was based on four Phase III trials showing mean HbA1c reductions of 0.7% to 0.8% versus placebo at 24 weeks.

Two years later came the label change that redefined the drug's clinical significance. In December 2016, the FDA added a cardiovascular indication based on the EMPA-REG OUTCOME trial (N=7,020), which demonstrated a 38% relative risk reduction in cardiovascular death (3.7% vs. 5.9%, hazard ratio 0.62 to 95% CI 0.49 to 0.77, P<0.001) among patients with type 2 diabetes and established cardiovascular disease [5]. Empagliflozin became the first diabetes drug to receive an FDA-approved claim for reducing cardiovascular death.

The indication broadened again in February 2022. The FDA approved empagliflozin for adults with heart failure regardless of ejection fraction or diabetes status, based on the EMPEROR-Reduced (N=3,730) and EMPEROR-Preserved (N=5,988) trials [6][7]. EMPEROR-Reduced showed a 25% reduction in the composite of cardiovascular death or heart failure hospitalization (HR 0.75 to 95% CI 0.65 to 0.86, P<0.001). EMPEROR-Preserved, the first positive trial for any drug in heart failure with preserved ejection fraction (HFpEF), showed a 21% reduction in the same composite endpoint (HR 0.79 to 95% CI 0.69 to 0.90, P<0.001) [7].

In June 2023, the FDA approved empagliflozin for chronic kidney disease (CKD) at risk of progression in adults, based on the EMPA-KIDNEY trial (N=6,609). That trial showed a 28% reduction in the composite of kidney disease progression or cardiovascular death (HR 0.72 to 95% CI 0.64 to 0.82, P<0.001) [8]. The CKD approval was notable because it included patients without diabetes. Roughly 46% of EMPA-KIDNEY participants did not have type 2 diabetes.

Dr. Robert Califf, then FDA Commissioner, noted in the agency's approval announcement that "expanding treatment options for chronic kidney disease is a priority, given that approximately 37 million Americans live with CKD and many progress to dialysis."

European Union: EMA Marketing Authorization

The European Medicines Agency granted marketing authorization for empagliflozin on May 22, 2014, slightly ahead of the FDA, under the brand name Jardiance [9]. The initial indication covered type 2 diabetes in adults as monotherapy (when metformin is inappropriate) or as add-on combination therapy.

The EMA's Committee for Medicinal Products for Human Use (CHMP) recommended a label extension for cardiovascular death reduction in 2017, aligning with the EMPA-REG OUTCOME data. A second major label expansion followed in 2022, when the EMA approved empagliflozin for symptomatic chronic heart failure in adults [9]. The EMA's heart failure indication language differs subtly from the FDA's. The European label specifies "symptomatic chronic heart failure" without the same granular ejection fraction breakdowns, reflecting a broader class-level framing.

Empagliflozin is also available in the EU as a fixed-dose combination with metformin (Synjardy) and as a fixed-dose combination with linagliptin (Glyxambi), both approved by the EMA [9]. These combinations do not carry the heart failure or CKD indications.

As of 2025, the EMA had not yet approved a standalone CKD indication for empagliflozin, even though the EMPA-KIDNEY data were published in January 2023. The regulatory submission for this indication was filed with the EMA in late 2023, and a CHMP opinion was anticipated during 2024 to 2025. Clinicians in EU member states already prescribe empagliflozin off-label for CKD based on published trial evidence and 2024 KDIGO guidelines, which recommend SGLT2 inhibitors as first-line therapy for CKD with an eGFR of 20 to 45 mL/min/1.73 m² [10].

United Kingdom: MHRA and NICE Guidance

When the UK left the European Union on January 31, 2020, empagliflozin's existing EMA marketing authorization was automatically converted into a UK marketing authorization under the MHRA (Medicines and Healthcare products Regulatory Agency). The drug retained all EU-approved indications at the time of conversion, including type 2 diabetes and the cardiovascular death reduction claim.

The MHRA subsequently approved the heart failure indication for empagliflozin in 2022, following its own regulatory review that ran parallel to, but independent of, the EMA process. This was one of the early examples of the MHRA exercising its post-Brexit independent assessment pathway for a major cardiovascular drug.

NICE (National Institute for Health and Care Excellence) has issued separate technology appraisals for empagliflozin across its indications. NICE Technology Appraisal TA336 (2015) recommended empagliflozin as an option for type 2 diabetes in combination with other glucose-lowering drugs. For heart failure, NICE TA929 (2023) recommended empagliflozin for symptomatic chronic heart failure with reduced or preserved ejection fraction in adults, making it available on the NHS. NICE's cost-effectiveness threshold analysis concluded that empagliflozin's incremental cost-effectiveness ratio (ICER) fell below £20,000 per quality-adjusted life year (QALY) gained, meeting the standard threshold for NHS reimbursement [11].

Dr. Andrew Clark, Professor of Clinical Cardiology at the University of Hull and a contributor to UK heart failure guidelines, stated: "The approval of SGLT2 inhibitors for heart failure with preserved ejection fraction fills a gap that existed for decades. We had no proven therapies for this condition until these trial results."

Canada: Health Canada Approvals

Health Canada approved empagliflozin in 2014 for type 2 diabetes, with a similar label to the FDA and EMA approvals. The cardiovascular benefit claim was added following submission of EMPA-REG OUTCOME data.

Health Canada approved the heart failure indication for empagliflozin in 2022, covering adults with heart failure with reduced ejection fraction (HFrEF). The HFpEF indication followed separately. The Canadian regulatory pathway for empagliflozin has generally tracked 6 to 12 months behind FDA decisions, reflecting Health Canada's independent review timelines.

The Canadian Drug Expert Committee (CDEC) of CADTH (now Canada's Drug Agency) recommended empagliflozin for reimbursement in heart failure, conditional on a price reduction [12]. Provincial drug plans implemented coverage over the subsequent 12 to 18 months, with Ontario and British Columbia among the first provinces to list empagliflozin for heart failure on their formularies.

Prescribing patterns in Canada differ from US norms. Canadian physicians are more likely to initiate SGLT2 inhibitors through endocrinology or internal medicine referral rather than primary care, partly reflecting formulary access restrictions that require specialist authorization in several provinces.

Regulatory Differences That Affect Clinical Practice

The four regulatory agencies do not approve identical label language, and these differences have real clinical implications. The FDA's heart failure indication covers empagliflozin "to reduce the risk of cardiovascular death and hospitalization for heart failure in adults with heart failure," without specifying ejection fraction boundaries. The EMA uses "symptomatic chronic heart failure." Health Canada initially split the approval by ejection fraction category.

Dose recommendations are consistent across markets: 10 mg once daily for all approved indications. The 25 mg dose is approved for type 2 diabetes glycemic control but is not used for heart failure or CKD. No dose adjustment is required for eGFR down to 20 mL/min/1.73 m², though all four agencies note that the glycemic efficacy diminishes at lower eGFR values while the cardio-renal benefits persist [4][8].

Contraindications are uniform. All four regulators contraindicate empagliflozin in patients on dialysis, those with type 1 diabetes (risk of diabetic ketoacidosis), and individuals with known hypersensitivity. The FDA and EMA both include warnings about Fournier's gangrene (necrotizing fasciitis of the perineum), a rare but serious adverse event identified through post-marketing surveillance with an estimated incidence of fewer than 1 in 10,000 patient-years [4].

Post-Marketing Safety Signals Across Jurisdictions

All four agencies have issued similar safety communications regarding SGLT2 inhibitors as a class. The most significant post-marketing safety signal for empagliflozin is euglycemic diabetic ketoacidosis (euDKA), where patients develop ketoacidosis with near-normal blood glucose levels [13]. The FDA issued a Drug Safety Communication in 2015 warning of this risk across all SGLT2 inhibitors. The EMA, MHRA, and Health Canada followed with parallel advisories.

The EMPA-REG OUTCOME trial reported genital infections in 6.4% of empagliflozin-treated patients versus 1.8% in the placebo group [5]. This adverse effect is mechanism-related (increased urinary glucose promotes yeast overgrowth) and is consistent across all regulatory jurisdictions. Lower limb amputation risk, a concern initially raised with canagliflozin in the CANVAS trial, has not been observed with empagliflozin in any major trial or post-marketing analysis. Both the FDA and EMA have clarified that the amputation signal appears specific to canagliflozin rather than a class effect.

Pipeline: Upcoming Regulatory Decisions

Boehringer Ingelheim has filed or is preparing regulatory submissions in several additional areas. An empagliflozin formulation for pediatric type 2 diabetes (DINAMO trial, N=158) has been reviewed by the FDA, which granted approval in June 2023 for patients aged 10 years and older [14]. The EMA and Health Canada pediatric reviews remain in progress.

A fixed-dose triple combination of empagliflozin, linagliptin, and metformin is under evaluation in certain markets. The EMPA-KIDNEY CKD indication continues to work through EMA and Health Canada review processes. SGLT2 inhibitor use in type 1 diabetes remains off-label in all four jurisdictions due to the high risk of ketoacidosis, with no current regulatory submissions planned for this population.

The 2024 ADA Standards of Care recommend SGLT2 inhibitors (including empagliflozin) as preferred second-line therapy after metformin for type 2 diabetes patients with established cardiovascular disease, heart failure, or CKD, regardless of HbA1c level [15]. The 2024 KDIGO CKD guidelines recommend SGLT2 inhibitors for all patients with CKD and an eGFR of 20 to 45 mL/min/1.73 m², or with albuminuria, independent of diabetes status [10]. These guideline positions are reflected in reimbursement criteria across all four markets, though formulary access timelines vary.